Skip to main content
SpringerLink
Log in

Coagulation and cancer: Implications for diagnosis and management

  • Seminar
  • Published:
Pathology & Oncology Research

Abstract

Coagulation disorders are a common problem in neoplastic patients and many factors contribute to increase the risk of thromboembolic events in these patients. An hypercoagulable state is induced by malignant cells interacting directly with hemostatic system and activating the coagulation cascade. More sensitive tests to assess an hypercoagulable state in cancer patients have been developed; even though these tests are always altered in cancer patients, none of them possess a clinical significance in terms of predictive value for the occurence of thromboembolism and disease prognosis in the individual patient. The most frequent thromboembolic complications in cancer patients are deep vein thrombosis of the lower extremities and pulmonary embolism; therefore, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura or haemolytic uremic syndrome are special manifestations of neoplastic disease. Diagnosis of idiopathic deep vein thrombosis, in the absence of other risk factors, could indicate the presence of occult malignant disease; however, the need for an extensive work-up to detect malignancy is still controversial. Neoplastic patients showing a thromboembolic event should be treated with unfractioned heparin or, alternatively, with low molecular weight heparins. In order to prevent recurrence, the administration of heparin should be associated and followed by an oral anticoagulant drug. In recent years new approaches in anti-aggregation therapy have been studied, such as COX-inhibitors, cicaprost and ReoPro; further studies are needed to determine the usefulness of these molecules in treatment of malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adany R: Intracellular factor XIII: cellular distribution of factor XIII subunit A in humans. Semin Thromb Hemost 22:399–408, 1996.

    Article  CAS  PubMed  Google Scholar 

  2. Bardos H, Juhansz A, Repassy G, et al: Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Thromb Haemost 80:767–772, 1998.

    CAS  PubMed  Google Scholar 

  3. Baron JA, Gridley G, Weiderpas E, et al: Venous thromboembolism and cancer. Lancet 351:1077–1080, 1998.

    Article  CAS  PubMed  Google Scholar 

  4. Bastida E, Ordinas A, Jamieson GA: Differing platelets aggregating effects by two tumor cells lines: absence of a role for platelet-derived ADP. Am J Hematol 11:367–378, 1981.

    Article  CAS  PubMed  Google Scholar 

  5. Bergqvist D, Burmark US: Low-molecular-weight heparin started before surgery as prophylaxis against deep-vein thrombosis: 2500 versus 5000 anti-Xa units in 2070 patients. Br J Surg 82:496–501, 1995.

    Article  CAS  PubMed  Google Scholar 

  6. Bertomeu MC, Gallo S, Lauri D Levine MN, et al: Chemotherapy enhances endothelial reactivity to platelets. Clin Expl Metastasis 8:511–518, 1990.

    Article  CAS  Google Scholar 

  7. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 5:1–26, 1978.

    CAS  PubMed  Google Scholar 

  8. Bottasso B, Mari D, Coppola R, et al: Hypercoagulability and hyperfibrinolysis in patients with melanoma. Thromb Res 81:345–352, 1996.

    Article  CAS  PubMed  Google Scholar 

  9. Brown LE, Detmar M, Claffey KP: Vascular permeability factor/vascular endothelial growht factor: a multifunctional angiogenesis factor. In: Goldberg ID, Rosen EM, eds. Regulation of Angiogenesis. Basel Birgkhauser Verlag, 233–269;

  10. Buccheri G, Ferrigno D, Ginardi C, et al: Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 33:50–55, 1997.

    Article  CAS  PubMed  Google Scholar 

  11. Calvo FA, Hidalgo OF, Gonzales F, et al: Urokinase combination chemotherapy in small cell lung cancer. A phase II study. Cancer 70:2624–2630, 1992.

    Article  CAS  PubMed  Google Scholar 

  12. Carey MG, Rodgers GM: Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 59:65–73, 1998.

    Article  CAS  PubMed  Google Scholar 

  13. Chahinian AP, Propert KJ, Ware JH, et al: A randomized trial of anticoagulation with warfarin and alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7:993–1002, 1989.

    CAS  PubMed  Google Scholar 

  14. Chan A, Woodruff RK: Complication and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust NZ J Med 22:119–122, 1992.

    CAS  Google Scholar 

  15. Chen YQ, Trikha M, Gao X, et al: Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. Int J Cancer 72:642–648, 1997

    Article  CAS  PubMed  Google Scholar 

  16. Clauss M, Gerlach M, Geralach H, et al: Vascular permeabiliy factor: a tumor-derived polypeptide that induce endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535–1545, 1990.

    Article  CAS  PubMed  Google Scholar 

  17. Colman RW, Rubin RN: Disseminated intravascular coagulation due to malignancy. Semin Oncol 17:140–146, 1990.

    Google Scholar 

  18. Cornuz J, Pearson SD, Creager MA, et al: Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 60:257–277, 1996.

    Google Scholar 

  19. Cybulsky MI, Chan MKW, Movat HZ. Acute inflammation and microthrombosis induced by endotoxin, interleukin-1 and tumor necrosis factor and their implication in gram negative infection. Lab Invest 58:365–368, 1988.

    CAS  PubMed  Google Scholar 

  20. DeLisser HM, Christofidou-Solomidou M, Strieter RM, et al: Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am JPathol 151:671–677, 1997

    Google Scholar 

  21. Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 75:329–336, 1990.

    CAS  PubMed  Google Scholar 

  22. Dolovich L, Ginsberg JS: Low-molecular weight heparins in the treatment of venous thromboembolism. Vessels 3:4–11, 1997.

    Google Scholar 

  23. Donati MB, Gambacorti-Passerinin C, et al: Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res 46: 6471–6474, 1986.

    CAS  PubMed  Google Scholar 

  24. Edwards RL, Rickles FR, Cronlund M: Mononuclear cell tissue factor generation. J Lab Clin Med 98:917–928, 1981.

    CAS  PubMed  Google Scholar 

  25. Eldor A: Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Baillieres Clin Haematol 11:475–495, 1998.

    Article  CAS  PubMed  Google Scholar 

  26. ENOXAN Study Group: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep-vein thrombosis in elective cancer surgery: a double-blind randomised multicentre trial with venography assessment. Br J Surg 84:1099–1103, 1997.

    Article  Google Scholar 

  27. Esmon CT: Possible involvment of cytokines indiffuse intravascular coagulation and thrombosis. Baillieres Clin Haematol 7:453–468, 1994.

    Article  CAS  PubMed  Google Scholar 

  28. Falanga A, Rickles FR: Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173–182, 1999.

    Article  CAS  PubMed  Google Scholar 

  29. Fisher B, Costantino JP, Wickerham L, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Projects P-1 Study. J Natl Cancer Inst 90:1371–1388, 1998.

    Article  CAS  PubMed  Google Scholar 

  30. Fournier DB, Gordon GB: COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl 34:97–102, 2000.

    Article  CAS  PubMed  Google Scholar 

  31. Francis JL, Biggerstaff J, Amirkhosravi A: Hemostasis and Malignancy. Semin Thromb Hemost 24:93–109, 1998.

    Article  CAS  PubMed  Google Scholar 

  32. Frishman WH, Burns B, Atac B, et al: Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa receptor. Am Heart J 130:877–892, 1995.

    Article  CAS  PubMed  Google Scholar 

  33. Ghosh BC, Chiffon EE: Malignant tumors with superior vena cava obstruction. NY State J Med 73:283–289, 1973.

    CAS  Google Scholar 

  34. Girolami A, Prandoni P, Zanon E, et al: Venous thrombosis of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinolysis 10:455–457, 1999.

    Article  CAS  PubMed  Google Scholar 

  35. Glassman AB: Hemostatic abnormalities associated with cancer and its therapy. Ann Clin Lab Sci 27:391–395, 1997.

    CAS  PubMed  Google Scholar 

  36. Goldeberg MA, Ginsburg D, Mayer RJ, et al: Is Heparin administration necessary during induction chemotherapy for patients with acute promielocytic leukaemia? Blood 69:187–191, 1987.

    Google Scholar 

  37. Goldeberg RJ, Seneff M, Gore JM, et al: Occult malignant neoplasm in patients with deep vein thrombosis. Arch Intern Med 147:251–253, 1987.

    Article  Google Scholar 

  38. Gordon LI, Kwaan HC: Thrombotic microangiopaty manifesting as thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost 25:217–221, 1999.

    Article  CAS  PubMed  Google Scholar 

  39. Gouin-Thibault I, Samama MM: Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Haemost 25:167–172, 1999.

    Article  CAS  Google Scholar 

  40. Gralnick HR, Abrell BA: Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Hematol 24:89–99, 1973.

    Article  CAS  Google Scholar 

  41. Griffin MR, Stanson AW, Brown ML, et al: FJ. Deep-vein thrombosis and pulmonary embolism: risk of subsequent malignant neoplasms. Arch Intern Med 147:1907–1901, 1987.

    Article  CAS  PubMed  Google Scholar 

  42. Hayes R, Chesebro JH, Fuster V, et al: Anthithrombotic effects of abciximab. Am J Cardiol 85:1167–1172, May 2000.

    Article  CAS  PubMed  Google Scholar 

  43. Hasui Y, Marutsuka K, Nishi S, et al: The content of urokinasetype plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 151:16–19; 1994.

    CAS  PubMed  Google Scholar 

  44. Hejna M, Raderer M, Zielinski CC: Inhibition of metastases by anticoagulants. JNCI 91:22–36, 1999.

    CAS  PubMed  Google Scholar 

  45. Hienert G, Kirchheimer JC, Christ G, et al: Plasma urokinasetype plasminogen activator correlates to bone scintigraphy in prostatic carcinoma. Eur Urol 15:256–258, 1988.

    CAS  PubMed  Google Scholar 

  46. Hiettarachchi JK, Lok J, Prins MH, et al: Undiagnosed malignancy in patients with deep vein thrombosis, Cancer 83:180–185, 1998.

    Article  Google Scholar 

  47. Honn KV, Busse WD, Sloane BE Prostacyclin and thromboxane. Implications for their role in tumor cell metastasis. Biochem Pharmacol 32:1–11, 1983.

    Article  CAS  PubMed  Google Scholar 

  48. Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science 212:1270–1272, 1981.

    Article  CAS  PubMed  Google Scholar 

  49. Honn KV, Tang DG, Crissman JD: Platelets and cancer metastasis: a casual relationship? Cancer Metastasis Rev 11:325–351, 1992.

    Article  CAS  PubMed  Google Scholar 

  50. Hotton KM, Khorsand M, Hank JA, et al: A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary métastases: a case of fatal central nervous system thrombosis. Cancer 88:1892–1901, 2000.

    Article  CAS  PubMed  Google Scholar 

  51. Hull R, Delmore T, Carter C, et al: Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 306:189–194, 1982.

    CAS  PubMed  Google Scholar 

  52. Kakkar AK, Williamson RCN: Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 25:239–244, 1999.

    Article  CAS  PubMed  Google Scholar 

  53. Karpakin S, Perlstein E: Role of platelets in tumor cells métastases. Ann Intern Med 95:636–641, 1981.

    Google Scholar 

  54. Lacotte L, Thierry A, Delwail V, et al: Thrombotic thrombocytopenic purpura during interferon alpha tretment for chronic myelogenous leukemia. Acta Haematol 102:160–162; 2000.

    Article  CAS  PubMed  Google Scholar 

  55. Lebeau B, Chastang CL, Brechot JM: Subcutaneous heparin treatment increases complete response rate and overall survival in small cell lung cancer. Lung Cancer 7 (Suppl): 129–134, 1991.

    Google Scholar 

  56. Lee AYY, Levine MN: The thrombophilic state induced by therapeutic agents. Semin Thromb Haemost 25:137–145, 1999.

    Article  CAS  Google Scholar 

  57. Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 334:677–681, 1996.

    Article  CAS  PubMed  Google Scholar 

  58. Levine M, Hirsh J, Gent M, et al: Double-bind randomized trial of very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886–889, 1994.

    Article  CAS  PubMed  Google Scholar 

  59. Levine M, Hirsh J: The diagnosis and treatment of thrombosis in the cancer patient. Semin Oncol 17:160–171, 1990.

    CAS  PubMed  Google Scholar 

  60. Levine MN, Lee AYY: Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 25:245–249, 1999.

    Article  CAS  PubMed  Google Scholar 

  61. Lhindal AK, Sandset PM, Abildgaard U: Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. Haemostasis 20:253–262, 1990.

    Google Scholar 

  62. Lopez Y, Paloma MJ, Rifon J, et al: Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res 15:71–78, 1999.

    Article  Google Scholar 

  63. Ludwig J, Kentos A, Creiner L, et al: Disseminated intravascular coagulation syndrome as manifestation of breast adenocarcinoma metastasis. Rev Med Brux 18:385–388, 1997.

    CAS  PubMed  Google Scholar 

  64. Luzzatto G, Schafer AI: The prethrombotic state in cancer. Seminars in Ocology 17:147–159, 1990.

    CAS  Google Scholar 

  65. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60(5): 1306–11; 2000.

    CAS  PubMed  Google Scholar 

  66. Min KW, Gyorkey F Sato C: Mucin producing adenocarcinomas and nonbacterial thrombotic endocarditis. Cancer 45:2374–2382; 1980.

    Article  CAS  PubMed  Google Scholar 

  67. Miyake H, Hara I, Yamanaka K, et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14:535–541, 1999.

    CAS  PubMed  Google Scholar 

  68. Monreal M, Lafoz E, Casals A, et al: Occult cancer in patients with deep vein thrombosis: a systematic approach. Cancer 67:541–545, 1991.

    Article  CAS  PubMed  Google Scholar 

  69. Monreal M, Prandoni P: Venous thromboembolism as first manifestation of cancer. Semin Thromb Hemost 25:131–136; 1999.

    Article  CAS  PubMed  Google Scholar 

  70. Muszbek L, Ádány R, Mikkola H: Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 33:357–421, 1996.

    Article  CAS  PubMed  Google Scholar 

  71. Nicholson GL, Custead SE: Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interaction as a model for assessing vascular integrity. Cancer Res 45:331–336, 1985.

    Google Scholar 

  72. Nie D, Tang K, Szekeres K, et al: Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann N Y Acad Sci 905:165–176, 2000.

    CAS  PubMed  Google Scholar 

  73. Newman PJ: The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci 714:165–174, 1994.

    Article  CAS  PubMed  Google Scholar 

  74. Nordstrom M, Lindblad B, Anderson H et al: Deep vein thrombosis and occult malignancy: an epidemiological study. BMJ 308:891–894, 1994.

    CAS  PubMed  Google Scholar 

  75. Oberhoff C, Winkler UH, Tauchert AM, et al: Adjuvant CMF chemotherapy in patients with breast cancer: result on blood coagulation and fibrinolysis. Zentralbl Gynakol 119:211–217, 1997.

    CAS  PubMed  Google Scholar 

  76. O’Connor NT Cederholm-Williams SA, Fletcher EW, et al: Significance of idiopathic deep venous thrombosis. Postgrad Med J 147:1907–1911, 1987.

    Google Scholar 

  77. Ohtake N, Kurita S, Fukabory Y, et al: Clinical study on prostate cancer initially presenting with disseminated intravascular coagulation syndrome. Hinyokika Kiyo 44:387–390, 1998.

    CAS  PubMed  Google Scholar 

  78. Owen CA, Bowie EJW: Chronic intravascular coagulation syndromes, a summary. Mayo Clin Proc 49: 673–679, 1974.

    PubMed  Google Scholar 

  79. Ozguroglu M, Arun B, Erzin Y, et al: Serum cardiolipin antibodies in cancer patient with thromboembolic events. Clin Appl Thromb Hemost 5:181–184, 1999.

    Article  CAS  PubMed  Google Scholar 

  80. Porta C, Danova M, Riccardi A, et al: Cancer Chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 74:570–574, 1999.

    Article  CAS  PubMed  Google Scholar 

  81. Prandoni P, Lensing AWA, Buller HR, et al: Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 339:441–445, 1992.

    Article  CAS  PubMed  Google Scholar 

  82. Prandoni P, Lensing AWA, Buller HR, et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128–1133, 1992.

    CAS  PubMed  Google Scholar 

  83. Prandoni P, Lensing AWA, Cogo Cuppini S, et al: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7; 1996.

    CAS  PubMed  Google Scholar 

  84. Prandoni P, Piccioli A, Girolami A: Cancer and venous thromboembolism: an overview. Hematologica 84:437–445, 1999.

    CAS  Google Scholar 

  85. Prandoni P: Antithrombotic strategies in patients with cancer. Thromb Haemost 78:141–144, 1997.

    CAS  PubMed  Google Scholar 

  86. Probst-Cousin S, Rickert CH, Gullotta F: Factor XIIa-immunoreactivity in tumors of the central nervous system. Clin Neuropathol 17:79–84, 1998.

    CAS  PubMed  Google Scholar 

  87. Raveh E, Cohen M, Shpitzer T, et al: Carcinoma of the thyroid: a cause of hypercoagulability? Ear Nose Throat J 74:110–112, 1995.

    CAS  PubMed  Google Scholar 

  88. Rayson D, Ingle JN, Pruthi RH: Thrombosis of the internal jugular vein: a rare manifestation of the hypercoagulability of malignancy. Cancer Invest 16:319–321, 1998.

    Article  CAS  PubMed  Google Scholar 

  89. Rella C, Caviello M, Giotta F et al: A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 40:151–159, 1996.

    Article  CAS  PubMed  Google Scholar 

  90. Rickles FR, Edwards RL, Barb C, et al: Abnormalities of blood coagulation in patients with cancer. Cancer 51:301–307, 1983.

    Article  CAS  PubMed  Google Scholar 

  91. Rickles FR, Levine M, Edwards RL: Hemostatic alterations in cancer patients. Cancer Metastasis Rev 11:237–248, 1992.

    Article  CAS  PubMed  Google Scholar 

  92. Schafer AI: Bleeding and thrombosis in the myeloproliferative disorders: Blood 69:187–191, 1987.

    Google Scholar 

  93. Schneider MR, Schirner M: Antimetastatic prostacyclin analogues. Drugs Future 18:29–48, 1993.

    Google Scholar 

  94. Schirner M, Schneider M: Cicaprost does not affect tumor inhibitory potential of cytostatic drugs. Anticancer Res 13:743–746, 1993.

    CAS  PubMed  Google Scholar 

  95. Shirner M, Shneider MR: Cicaprost inhibits metastases of animal tumors. Prostaglandins 42:451–461, 1991.

    Article  Google Scholar 

  96. Shirner M, Lichter RB, Schneider MR: The stable prostacyclin analogue cicaprost inhibits metastasis to lungs and lymph nodes in the 1376NF MTLn3 rat mammary carcinoma. Clin Exp Metastasis 12:24–30, 1994.

    Article  Google Scholar 

  97. Schulman S, Granqvist S, Holmstrom M, et al. Duration of Anticoagulant Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336:393–398, 1997.

    Article  CAS  PubMed  Google Scholar 

  98. Semeraro N, Colucci M: Tissue factor in health and disease. Thromb Haemost 78:759–764, 1997.

    CAS  PubMed  Google Scholar 

  99. Shands JW: Macrophage procoagulants. Hemostasis 14:373–377, 1984.

    Google Scholar 

  100. Silverstein TR, Nachman RL: Cancer and clotting: Trousseau warning. N Engl J Med 327:1163–1164, 1992.

    CAS  PubMed  Google Scholar 

  101. Sorensen HT, Mellemkiaer L, Steffensen FH, et al: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169–1173, 1998.

    Article  CAS  PubMed  Google Scholar 

  102. Skelly MM, Troy A, Duffy MJ, et al: Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3:1837–1840, 1997.

    CAS  PubMed  Google Scholar 

  103. Sun NCJ, McAfee WM, Hum GJ, et al: Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 71:10–16; 1979.

    CAS  PubMed  Google Scholar 

  104. Tang DG, Chen YQ, Newman PJ, et al: Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem 268:22883–22894, 1993.

    CAS  PubMed  Google Scholar 

  105. Tetu B, Brisson J, Lapointe H, et al: Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 29:979–985, 1998.

    Article  CAS  PubMed  Google Scholar 

  106. The Columbus Investigators. Low Molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337:657–662, 1997.

    Article  Google Scholar 

  107. Thornes RD: Fibrinolytic therapy of leukemia. J R Coll Surg Ireland 6:123–128, 1971.

    Google Scholar 

  108. Trikha M, Raso E, Cai Y, et al: Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate 35:185–192, 1998.

    Article  CAS  PubMed  Google Scholar 

  109. Trousseau A: Phlegmasia alba dolens. Lecture on clinical medicine, delivered at the Hotel-Dieu, Paris. London: New Sydenham Society, 281–295, 1872.

    Google Scholar 

  110. Ustundag Y, Can U, Benli S, et al: N. Internal carotid occlusion in a patient with malignant peritoneal mesothelioma: it is a sign of malignancy-related thrombosis? Am J Med Sci 319:265–267, 2000.

    Article  CAS  PubMed  Google Scholar 

  111. Vallejo CT Rabinovich MG, Perez JE, et al: High-dose cisplatin with dipyridamole in advanced non-small cell lung cancer. A Grupo Oncologico Cooperativo del Sur Study. Am J Clin Oncol Cancer Clin Trial 18:185–188, 1995.

    CAS  Google Scholar 

  112. Van de Water L, Tracy PB, Aronson D, et al: Tumor cell generation of thrombin via prothrombinase assembly. Cancer Res 45: 5521–5525, 1985.

    Google Scholar 

  113. von Tempelhoff GF, Dietrich M, Niemann F, et al: Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 77:456–461, 1997.

    Google Scholar 

  114. Wada H Sakuragawa N, Mari Y, et al: Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 60:273–278, 1999.

    Article  CAS  PubMed  Google Scholar 

  115. Winkley JM, Adams HP jr. Potential role of abciximab in ischemic cerebrovascular disease. Am J Cardiol 85:47C-51C, 2000.

    Article  CAS  PubMed  Google Scholar 

  116. Wester JPJ, deValk HW, Nieuwenhuis HK, et al: Risk factors for bleed during treatment of acute venous thromboembolism. Thromb Haemost 76:682–688, 1996.

    CAS  PubMed  Google Scholar 

  117. Zacharski TR, Henderson WG, Rickles FR, et al: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study 75. Cancer 53:2046–2052, 1984.

    Article  CAS  PubMed  Google Scholar 

  118. Zacharski LR, Wojtukiewicz MZ, Costantini W, et al: Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 18:104–116, 1992.

    Article  CAS  PubMed  Google Scholar 

  119. Zurbron KH, Gram J, Glander K, et al: Influence of cytostatic treatment on the coagulation system and fibrinolysis in patient with non-Hodgkin’s lymphomas and acute leukemias. Eur J Haematol 47:55–59, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Public Health, University of L’Aquila, Via San Sisto 22/E, 67100, L’Aquila, Italy

    M. F. Loreto, Massimo De Martinis, M. P. Corsi, M. Modesti & L. Ginaldi

Authors
  1. M. F. Loreto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo De Martinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. P. Corsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Modesti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Ginaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo De Martinis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loreto, M.F., De Martinis, M., Corsi, M.P. et al. Coagulation and cancer: Implications for diagnosis and management. Pathol. Oncol. Res. 6, 301–312 (2000). https://doi.org/10.1007/BF03187336

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03187336

Keywords

Search

Navigation